Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price reduced by research analysts at Piper Sandler from $875.00 to $855.00 in a report released on Monday,Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price objective suggests a potential upside of 37.40% from the company’s current price.
Other analysts also recently issued research reports about the company. Sanford C. Bernstein dropped their target price on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Citigroup reiterated a “neutral” rating and issued a $700.00 price objective (down from $900.00) on shares of Regeneron Pharmaceuticals in a report on Monday. Evercore increased their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $800.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $810.91.
Get Our Latest Research Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Price Performance
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $8.22 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.1 EPS for the current year.
Insider Buying and Selling at Regeneron Pharmaceuticals
In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 6.97% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. WPG Advisers LLC boosted its position in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares in the last quarter. SHP Wealth Management purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $26,000. Titan Wealth CI Ltd purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $29,000. Board of the Pension Protection Fund bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. Institutional investors own 83.31% of the company’s stock.
Regeneron Pharmaceuticals News Roundup
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Negative Sentiment: Regeneron’s phase 3 melanoma trial for fianlimab missed its main goal, weakening confidence in a high-profile pipeline asset and contributing to analyst downgrades. Reuters article
- Neutral Sentiment: Citigroup reaffirmed its neutral rating on REGN but cut its price target to $700 from $900, signaling a more cautious valuation view. Tickerreport article
- Neutral Sentiment: Leerink Partners also reaffirmed a market perform rating and lowered its target to $641 from $792, reflecting reduced expectations after the trial setback. Benzinga article
- Positive Sentiment: Regeneron announced a strategic collaboration with Parabilis Medicines to develop novel antibody-Helicon conjugates, a pipeline-expanding deal that could eventually generate significant milestone payments and royalties. Yahoo Finance article
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- Iran Ceasefire Trade: 3 Energy Stocks to Own if Oil Falls to $80
- Willing and Abel: Berkshire’s New CEO Makes Huge Portfolio Changes in Q1
- Insider Buying Says Upstart Isn’t Down for the Count
- These Stocks Could Be the Biggest Winners of the 2026 Midterms
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
